Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $760,644 - $876,709
51,815 New
51,815 $802,000
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $676,961 - $993,604
57,467 New
57,467 $966,000
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $243,682 - $535,688
34,516 New
34,516 $443,000
Q2 2018

Aug 14, 2018

SELL
$2.26 - $3.84 $92,004 - $156,326
-40,710 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$2.39 - $4.01 $97,296 - $163,247
40,710 New
40,710 $97,000
Q4 2017

Feb 14, 2018

SELL
$2.51 - $4.4 $37,148 - $65,120
-14,800 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$2.4 - $2.94 $35,520 - $43,512
14,800
14,800 $37,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.